Entrectinib for the treatment of metastatic NSCLC: safety and efficacy

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol. 2019;30(5):781–787.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Jeon J, Holford TR, Levy DT, et al. Smoking and lung cancer mortality in the United States from 2015 to 2065: a comparative modeling approach. Ann Intern Med. 2018;169(10):684–693.
   PubMed Web of Science ®Google Scholar
• Key Findings | State of Lung Cancer | American Lung Association. Available from: https://www.lung.org/our-initiatives/research/monitoring-trends-in-lung-disease/state-of-lung-cancer/key-findings.html
   Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Kim D-W, Wu Y-L, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non–small-cell lung cancer. J Clin Oncol. 2018;36(22):2251–2258.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Riely GJ, Bang Y-J, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121–1126.
   PubMed Web of Science ®Google Scholar
• Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2017;12(11):1611–1625.
   Google Scholar
• Bergethon K, Shaw AT, Ignatius Ou S-H, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30(8):863–870.
   PubMed Web of Science ®Google Scholar
• Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta. 2009;1795(1):37–52.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
   PubMed Web of Science ®Google Scholar
• Amatu A, Sartore-Bianchi A, Bencardino K, et al. Tropomyosin Receptor Kinase (TRK) biology and the role of NTRK gene fusions in cancer. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(Supplement_8):viii5–viii15.
   Google Scholar
• Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15(12):731–747.
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19(11):1469–1472.
   PubMed Web of Science ®Google Scholar
• Farago AF, Le LP, Zheng Z, et al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2015;10(12):1670–1674.
   Google Scholar
• Farago AF, Taylor MS, Doebele RC, et al. Clinicopathologic features of non–small-cell lung cancer harboring an NTRK gene fusion. JCO Precis Oncol. 2018; (2):1–12. DOI:10.1200/PO.18.00037
   Google Scholar
• Solomon JP, Benayed R, Hechtman JF, et al. Identifying patients with NTRK fusion cancer. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(Supplement_8):viii16–viii22.
   Google Scholar
• Shaw AT, Camidge DR, Engelman JA, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol. 2012;30(15_suppl):7508.
   Web of Science ®Google Scholar
• Wu Y-L, Yang JC-H, Kim D-W, et al. Phase II study of crizotinib in east asian patients with ROS1-positive advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(14):1405–1411.
   PubMed Web of Science ®Google Scholar
• Michels S, Massutí B, Schildhaus H-U, et al. Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): a European phase II clinical trial. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019;14(7):1266–1276.
   Google Scholar
• Landi L, Chiari R, Tiseo M, et al. Crizotinib in MET-deregulated or ROS1-rearranged pretreated non-small cell lung cancer (METROS): a phase II, prospective, multicenter, two-arms trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2019;25(24):7312–7319.
   PubMed Web of Science ®Google Scholar
• Moro-Sibilot D, Cozic N, Pérol M, et al. Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(12):1985–1991.
   Google Scholar
• Liang Y, Wakelee HA, Neal JW. Relationship of driver oncogenes to long-term pemetrexed response in non–small-cell lung cancer. Clin Lung Cancer. 2015;16(5):366–373.
   PubMed Web of Science ®Google Scholar
• Chen Y-F, Hsieh M-S, Wu S-G, et al. Efficacy of pemetrexed-based chemotherapy in patients with ROS1 fusion-positive lung adenocarcinoma compared with in patients harboring other driver mutations in East Asian populations. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2016;11(7):1140–1152.
   Google Scholar
• Mazières J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(8):1321–1328.
   Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®) for non-small cell lung cancer (version 1.2020). [ cited 2019 Nov 23]. Available from: https://www.nccn.org/professionals/physician_gls/recently_updated.aspx
   Google Scholar
• Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2019;29Suppl4:iv192–iv237.. Updated 18 Sept.
   Google Scholar
• Gainor JF, Tseng D, Yoda S, et al. Patterns of metastatic spread and mechanisms of resistance to crizotinib in ROS1 positive non–small-cell lung cancer. JCO Precis Oncol. 2017;(1):1–13. DOI:10.1200/PO.17.00063
   PubMedGoogle Scholar
• Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(15):e443–445.
   PubMed Web of Science ®Google Scholar
• Patil T, Smith DE, Bunn PA, et al. The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13(11):1717–1726.
   Google Scholar
• Costa DB, Shaw AT, Ou S-HI, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non–small-cell lung cancer and brain metastases. J Clin Oncol. 2015;33(17):1881–1888.
   PubMed Web of Science ®Google Scholar
• Drilon A, Somwar R, Wagner JP, et al. A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(10):2351–2358.
   PubMed Web of Science ®Google Scholar
• Sun TY, Niu X, Chakraborty A, et al. Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small cell lung cancer. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2019;14(2):e21–e24.
   Google Scholar
• Lim SM, Kim HR, Lee J-S, et al. Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35(23):2613–2618.
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Takeda M, Yamamoto N, et al. Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget. 2018;9(34):23729–23737.
   PubMedGoogle Scholar
• Drilon A, Siena S, S-HI O, et al., Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400–409.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon BJ, Chiari R, et al. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2019;20(12):1691–1701.
   Web of Science ®Google Scholar
• Drilon A, Ou S-HI, Cho BC, et al. Repotrectinib (TPX-0005) is a next-generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent- front mutations. Cancer Discov. 2018;8(10):1227–1236.
   PubMed Web of Science ®Google Scholar
• Katayama R, Kobayashi Y, Friboulet L, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(1):166–174.
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Loriot Y, Kuo M-S, et al. Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers. Clin Cancer Res Off J Am Assoc Cancer Res. 2016;22(24):5983–5991.
   PubMed Web of Science ®Google Scholar
• Zou HY, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci U S A. 2015;112(11):3493–3498.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Martini J-F, Ou S-HI, et al. 1380PDEfficacy of lorlatinib in patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC) and ROS1 kinase domain mutations. Ann Oncol. 2018;29:viii495.
   Google Scholar
• Katayama R, Gong B, Togashi N, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun. 2019;10(1):3604.
   PubMedGoogle Scholar
• Cho BC, Drilon AE, Doebele RC, et al. Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). J Clin Oncol. 2019;37(15_suppl):9011.
   Web of Science ®Google Scholar
• Facchinetti F, Friboulet L. Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date. Lung Cancer Targets Ther. 2019;10:87–94.
   PubMed Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739.
   PubMed Web of Science ®Google Scholar
• Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020. DOI:10.1016/S1470-2045(19)30856-3.
   PubMed Web of Science ®Google Scholar
• Russo M, Misale S, Wei G, et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 2016;6(1):36–44.
   PubMed Web of Science ®Google Scholar
• Drilon A, Li G, Dogan S, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol Off J Eur Soc Med Oncol. 2016;27(5):920–926.
   PubMed Web of Science ®Google Scholar
• Drilon A, Nagasubramanian R, Blake JF, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 2017;7(9):963–972.
   PubMed Web of Science ®Google Scholar
• Hyman D, Kummar S, Farago A, et al. Abstract CT127: phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi). Cancer Res. 2019;79(13 Supplement):CT127–CT127.
   Google Scholar
• Drilon A, Zhai D, Deng W, et al. Abstract 442: repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations. Cancer Res. 2019;79(13 Supplement):442.
   Web of Science ®Google Scholar
• Ardini E, Menichincheri M, Ponti CD, et al. Abstract A243: characterization of NMS‐E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK‐dependent lymphoma and non‐small cell lung cancer models. Mol Cancer Ther. 2009;8(12 Supplement):A244–A244.
   Web of Science ®Google Scholar
• Menichincheri M, Ardini E, Magnaghi P, et al. Discovery of entrectinib: a new 3-aminoindazole as a potent Anaplastic Lymphoma Kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (pan-TRKs) inhibitor. J Med Chem. 2016;59(7):3392–3408.
   PubMed Web of Science ®Google Scholar
• Ardini E, Menichincheri M, Banfi P, et al., Entrectinib, a pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther. 2016;15(4):628–639.
   PubMed Web of Science ®Google Scholar
• Ardini E, Menichincheri M, Banfi P, et al. Abstract A232: in vitro and in vivo activity of NMS-E628 against ALK mutations resistant to Xalkori. Mol Cancer Ther. 2011;10(11 Supplement):A232–A232.
   Google Scholar
• Chong CR, Bahcall M, Capelletti M, et al. Identification of existing drugs that effectively target NTRK1 and ROS1 rearrangements in lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23(1):204–213.
   PubMed Web of Science ®Google Scholar
• Patel MR, Bauer TM, SV L, et al. STARTRK-1: phase 1/2a study of entrectinib, an oral pan-TRK, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2015;33(15_suppl):2596.
   Web of Science ®Google Scholar
• De Braud FG, Pilla L, Niger M, et al. Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2014;32(15_suppl):2502.
   Web of Science ®Google Scholar
• Roche. Rozlytrek (entrectinib) [ package insert]. U.S. food and drug administration website. [ cited 2019 Nov 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212725s000lbl.pdf
   Google Scholar
• Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):261–270.
   Web of Science ®Google Scholar
• Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–282.
   Web of Science ®Google Scholar
• Braud FGMD, Siena S, Barlesi F, et al. 1488PDEntrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol. 2019. DOI:10.1093/annonc/mdz260.010.
   PubMedGoogle Scholar
• Doebele R, Paz-Ares L, Farago AF, et al. Abstract CT131: entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001). Cancer Res. 2019;79(13 Supplement):CT131–CT131.
   Web of Science ®Google Scholar
• Hong DS, Bauer TM, Lee JJ, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(2):325–331.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Drilon A. TRK inhibitors in TRK fusion-positive cancers. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(Supplement_8):viii23–viii30.
   Google Scholar
• Omote S, Matsuoka N, Arakawa H, et al. Effect of tyrosine kinase inhibitors on renal handling of creatinine by MATE1. Sci Rep. 2018;8(1):9237.
   PubMedGoogle Scholar
• ESMO. Japan becomes the first country to approve entrectinib. [ cited Nov 17, 2019]. Available from: https://www.esmo.org/Oncology-News/Japan-Becomes-the-First-Country-to-Approve-Entrectinib
   Google Scholar
• FDA. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. [ cited 2019 Nov 17]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumorsand-ros-1-nsclc
   Google Scholar
• Deng W, Zhai D, Zhang X, et al. Abstract 1319: repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations. Cancer Res. 2019;79(13 Supplement):1319.
   Web of Science ®Google Scholar
• Ku BM, Bae YH, Lee KY, et al. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer. Invest New Drugs. 2019. DOI:10.1007/s10637-019-00795-3.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2012;18(5):1472–1482.
   PubMed Web of Science ®Google Scholar
• Lindsay CR, Blackhall FH. Direct Ras G12C inhibitors: crossing the rubicon. Br J Cancer. 2019;121(3):197–198.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.
   PubMed Web of Science ®Google Scholar